Skip to main content

Common Medicines Tied to Urinary Incontinence


By David Douglas
NEW YORK (Reuters Health) Jun 11 - An apparent association between some common medications, including antihistamines and angiotensin II receptor blockers (ARBs), and urinary incontinence (UI) suggests a need for further study, researchers say.
Dr. Susan A. Hall of the New England Research Institutes, Watertown, Massachusetts, lead author of a report online May 15 in the Journal of Urology, told Reuters Health by email that her team found some associations that were not previously documented.
But, she added, the cross-sectional design of the research can't prove causality.
The population-based epidemiological study involved more than 5,500 men and women aged 30 to 79 years. Nine percent of women and 4.6% of men had urinary incontinence -- and these individuals were significantly older than those without such symptoms.
The prevalence of UI was then examined in users of 25 medication groups after adjustments for known urinary incontinence risk factors.
For women, the prevalence was highest among users of antihistamines (28.4%) and ARBs (22.9%). In men, the prevalence of UI was highest among users of ARBs (22.2%), followed by loop diuretics (19.1%).
UI odds ratios of more than 1.7 were established for women using certain antihistamines (OR 1.75), beta receptor agonists (OR 1.73), ARBs (OR 2.07), estrogens (OR 1.90) and anticonvulsants (OR 1.75).
Among men only anticonvulsants were associated with urinary incontinence after final adjustments (OR 2.5). ARBs showed an adjusted association of borderline significance.
"Future epidemiologic studies," Dr. Hall concluded, "should consider whether new use of these drugs is associated with incident incontinence."

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more